Clinical Trial Update: Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis

View source ↗

Summary

Post-marketing surveillance study of Actimmune (interferon gamma-1b) in patients with severe, malignant osteopetrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopetrosis

Drugs mentioned

• ACTIMMUNE (interferon gamma-1b)

Snippet

Sponsor: InterMune | Conditions: Osteopetrosis | Status: COMPLETED